KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

G. Hartinger, Christian; A. Jakupec, Michael; Zorbas‐Seifried, Stefanie; Groessl, Michael; Egger, Alexander; Berger, Walter; Zorbas, Haralabos; J. Dyson, Paul; K. Keppler, Bernhard

doi:10.1002/cbdv.200890195

Public

KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

Shared by NobleBlocks on Oct 1, 2008 • 12:00 AM UTC

Authors:

Christian G. Hartinger

Michael A. Jakupec

Stefanie Zorbas‐Seifried

Abstract

Abstract The promising drug candidate indazolium trans ‐[tetrachlorobis(1 H ‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 ( Hartinger et al., J. Inorg. Biochem. 2006 , 100 , 891–904), the e...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!